IQVIA (IQV) Q1 2025 10-Q Quarterly Report
Filed: May 6, 2025Period ending Mar 31, 2025
Industrials
Services-Commercial Physical & Biological ResearchSEC EDGAR IQVIA (IQV) 10-Q quarterly report for Q1 2025, filed with SEC EDGAR on May 6, 2025 for the fiscal period ending Mar 31, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
IQVIA Q1 2025 10-Q Analysis
Risk Factors
- • New regulatory tax risk: EU OECD Pillar Two minimum 15% tax implemented 2024; no material impact YTD 2025 but ongoing evaluation amid global tax law changes
- • Updated financial risk: Raised equity repurchase authorization by $2B to total $13.725B; repurchased $425M of stock in Q1 2025 vs prior periods
- • Most impactful legal/compliance risk: Compliance with restrictive covenants on $14.389B indebtedness and amendment adding $1.985B incremental Term B-5 loan facility in March 2025
- • Operational risk: Restructuring costs rose to $29M in Q1 2025 from $15M to streamline global operations and reduce overcapacity through 2026
- • Market risk: Currency exposure with ~30% revenues in 60+ foreign currencies impacting reported results; constant currency revenue growth 3.5% offset by FX translation effects
IQVIA Q1 2025 Quarterly FinancialsXBRL
Revenue
$3.8B
▲ +2.5% YoY
Net Income
$249M
▼ -13.5% YoY
Operating Margin
13.0%
▼ -59bp YoY
Net Margin
6.5%
▼ -120bp YoY
EPS (Diluted)
$1.40
▼ -10.3% YoY
Operating Cash Flow
$568M
▲ +8.8% YoY
Source: XBRL data from IQVIA Q1 2025 10-Q filing on SEC EDGAR. All figures in USD.
Other IQVIA Quarterly Reports
Get deeper insights on IQVIA
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.